CG Oncology Inc. cash flow to debt ratio of -1.89K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

CG Oncology Inc.'s free cash flow has decreased 67.81% from $-78.95M last year to $-132.48M, signaling decreasing performance

CG Oncology Inc.'s debt to equity ratio is 0.01, which means that the company's assets are healthy financed, signaling financial stability.

CG Oncology Inc.'s debt has increased relative to shareholder equity from 0.00 last year to 0.01 today, signaling weakened financials

CG Oncology Inc. has a net cash position, so leverage is healthy.

CG Oncology Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

CG Oncology Inc.'s profit margin has increased (-53.39%) in the last year from -7.73K% to -3.60K%, signaling increasing performance

CG Oncology Inc.'s short-term assets of $759.48M exceed its short-term liabilities of $30.84M

CG Oncology Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

CG Oncology Inc.'s return on equity of -25.20%, is lower than 15.00%, indicating bad performance

CG Oncology Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

CG Oncology Inc. has insufficient public price history to evaluate earnings stability.

CG Oncology Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

CG Oncology Inc. has negative free cash flow, indicating cash burn

CG Oncology Inc.'s yearly earnings has decreased 82.87% since last year from $-88.04M to $-161.00M, signaling decreasing performance

CG Oncology Inc.'s yearly revenue has increased 254.70% since last year from $1.14M to $4.04M, signaling increasing performance

ROIC -24.30% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

CG Oncology Inc.'s 3-year revenue CAGR of 176.56% is positive, indicating growing revenue over the past 3 years

CG Oncology Inc. has insufficient public price history to evaluate revenue consistency.

CG Oncology Inc. has insufficient public price history to evaluate ROE consistency.

CG Oncology Inc. has insufficient data to evaluate this check.

CG Oncology Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

CG Oncology Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

CG Oncology Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

CG Oncology Inc. has insufficient data to evaluate this check.

CG Oncology Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

CG Oncology Inc. has a price-to-book ratio of 6.56x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

CG Oncology Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue